{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:05:21Z","timestamp":1790845521249,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEBA 22A0"],"award-info":[{"award-number":["MUHLEBA 22A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.09.017","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:46:08Z","timestamp":1728567968000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Changes in factors associated with inhaled antibiotic prescriptions for people with cystic fibrosis over time in the U.S."],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-1598","authenticated-orcid":false,"given":"Marianne S.","family":"Muhlebach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-4357","authenticated-orcid":false,"given":"Jane","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-6858","authenticated-orcid":false,"given":"Jonathan D.","family":"Cogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-9738","authenticated-orcid":false,"given":"Michael R.","family":"Kosorok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.09.017_bib0001","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.09.017_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jama.293.5.581","article-title":"Longitudinal Development of Mucoid Pseudomonas aeruginosa Infection and Lung Disease Progression in Children With Cystic Fibrosis","volume":"293","author":"Li","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2024.09.017_bib0003","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.017_bib0004","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.09.017_bib0005","unstructured":"CF-Trust, U. Summary of principles and standards of cystic fibrosis care. 2011 [cited 2016 September 19]."},{"key":"10.1016\/j.jcf.2024.09.017_bib0006","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcf.2009.03.001","article-title":"Implementation of European standards of care for cystic fibrosis\u2013control and treatment of infection","volume":"8","author":"Elborn","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.017_bib0007","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.09.017_bib0008","series-title":"Cystic fibrosis foundation patient registry","year":"2018"},{"key":"10.1016\/j.jcf.2024.09.017_bib0009","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols","volume":"67","author":"Taccetti","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.09.017_bib0010","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.4187\/respcare.08671","article-title":"The role of suboptimal concentrations of nebulized tobramycin in driving antimicrobial resistance in pseudomonas aeruginosa isolates in cystic fibrosis","volume":"66","author":"Moore","year":"2021","journal-title":"Respir Care"},{"key":"10.1016\/j.jcf.2024.09.017_bib0011","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The cystic fibrosis foundation patient registry. design and methods of a National Observational Disease Registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.09.017_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.017_bib0013","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.017_bib0014","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.09.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01241-2023","article-title":"Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain","volume":"63","author":"Kerem","year":"2024","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.09.017_bib0016","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1136\/bmjqs-2013-002369","article-title":"Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project","volume":"23","author":"Boyle","year":"2014","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.jcf.2024.09.017_bib0017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcf.2011.02.004","article-title":"Treatment intensity and characteristics of MRSA infection in CF","volume":"10","author":"Muhlebach","year":"2011","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.017_bib0018","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ppul.21383","article-title":"Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis","volume":"46","author":"Leahy","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.09.017_bib0019","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1128\/AAC.04123-14","article-title":"In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients","volume":"59","author":"Ratjen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2024.09.017_bib0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jcf.2017.02.008","article-title":"Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection","volume":"16","author":"Waters","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.017_bib0021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12890-018-0594-8","article-title":"Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients","volume":"18","author":"Garcia","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcf.2024.09.017_bib0022","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jcf.2018.01.008","article-title":"Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis","volume":"17","author":"Hong","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.017_bib0023","doi-asserted-by":"crossref","first-page":"18999","DOI":"10.1038\/s41598-020-75886-w","article-title":"Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function","volume":"10","author":"Duesberg","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2024.09.017_bib0024","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.09-1103","article-title":"The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis","volume":"137","author":"Amin","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.09.017_bib0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1164\/rccm.201908-1585OC","article-title":"Aspergillus Infections and Progression of Structural Lung Disease in Children with Cystic Fibrosis","volume":"201","author":"Breuer","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.017_bib0026","article-title":"Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States","author":"McGarry","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.017_bib0027","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ppul.21037","article-title":"Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population","volume":"44","author":"Watts","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.09.017_bib0028","first-page":"348","article-title":"Characteristics of U.S. CF Care centers with high MRSA prevalence","volume":"52","author":"Muhlebach","year":"2017","journal-title":"Ped. Pulm."},{"key":"10.1016\/j.jcf.2024.09.017_bib0029","series-title":"CF Patient Registry Annual Report","author":"Registry","year":"2021"},{"key":"10.1016\/j.jcf.2024.09.017_bib0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcf.2023.05.007","article-title":"The prevalence of children in the UK Cystic Fibrosis Registry on long term anti-Pseudomonas aeruginosa (PA) inhaled antibiotics who become culture negative for PA and a survey of practice for discontinuing treatment","volume":"23","author":"Gilchrist","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.017_bib0031","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2022.08.010","article-title":"Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - A European cystic fibrosis patient registry data analysis","volume":"22","author":"Orenti","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:27Z","timestamp":1738275087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324017855"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.017","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in factors associated with inhaled antibiotic prescriptions for people with cystic fibrosis over time in the U.S.","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}